LONG-ACTING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISM MITIGATES INFLAMMATION AND FIBROSIS IN MODELS OF NASH AND BILIARY FIBROSIS

被引：0
|
作者：
Wang, X. -Y. [1 ]
Weng, S. -Y. [1 ]
Kim, Y. O. [1 ]
Klein, T. [2 ]
Schuppan, D. [1 ,3 ]
机构：
[1] Inst Translat Immunol, Mainz, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(14)60791-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P629
引用
收藏
页码：S278 / S278
页数：1
相关论文
共 50 条
  • [21] Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats
    Marty, Vincent N.
    Farokhnia, Mehdi
    Munier, Joseph J.
    Mulpuri, Yatendra
    Leggio, Lorenzo
    Spigelman, Igor
    FRONTIERS IN NEUROSCIENCE, 2020, 14
  • [22] A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
    Gurung, Tara
    Shyangdan, Deepson S.
    O'Hare, Joseph Paul
    Waugh, Norman
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 : 363 - 386
  • [23] Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
    Underwood, Christina Rye
    Garibay, Patrick
    Knudsen, Lotte Bjerre
    Hastrup, Sven
    Peters, Gunther H.
    Rudolph, Rainer
    Reedtz-Runge, Steffen
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (01) : 723 - 730
  • [24] THE EFFECT OF A DUAL RECEPTOR GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON AGONIST, COTADUTIDE, ON SERUM METABOLOME IN BIOPSY PROVEN NON-CIRRHOTIC NASH WITH FIBROSIS
    Daniels, Samuel J.
    Robertson, Darren
    Challis, Benjamin
    Sanyal, Arun J.
    Shankar, Sudha S.
    HEPATOLOGY, 2022, 76 : S92 - S92
  • [25] Glucagon-Like Peptide-1 Receptor Agonists
    Edelman, Steven V.
    JOURNAL OF FAMILY PRACTICE, 2017, 66 (10): : S12 - S16
  • [26] The Glucagon-Like Peptide-1 Receptor-or Not?
    Pyke, Charles
    Knudsen, Lotte Bjerre
    ENDOCRINOLOGY, 2013, 154 (01) : 4 - 8
  • [27] Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist-Immunogenicity Profile Based on Preclinical and Clinical Studies
    Del Prato, Stefano
    Choi, In Young
    Kang, Jahoon
    Trautmann, Michael E.
    Yoon, Kun-Ho
    Sorli, Christopher H.
    DIABETES, 2018, 67
  • [28] Novel mono-lipidated dimeric glucagon-like peptide-1 receptor agonist with improved long-acting and hypoglycemic activity
    Sun, Lidan
    Han, Jing
    Chen, Xinyu
    Han, Yue
    Wu, Lingling
    Xia, E.
    RSC ADVANCES, 2019, 9 (17) : 9654 - 9662
  • [29] Impact of Glucagon-Like Peptide-1 Receptor Agonist on Gallbladder and Biliary Diseases
    Alchirazi, Khaled Alsabbagh
    Baliss, Michelle
    El Telbany, Ahmed
    Alsabbagh, Muaz
    Alsakarneh, Saqr
    Kiwan, Wissam
    Bilal, Mohammad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S132 - S132
  • [30] GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISM IMPROVES BIOCHEMICAL AND HISTOPATHOLOGICAL INDICES OF NONALCOHOLIC STEATOHEPATITIS (NASH) IN MICE
    Trevaskis, James L.
    Griffin, Peter
    Wittmer, Carrie
    Neuschwander-Tetri, Brent A.
    Brunt, Elizabeth M.
    Bilakovics, James M.
    Crogan-Grundy, Candace
    Lowe, Carolyn
    Parkes, David
    Roth, Jonathan D.
    HEPATOLOGY, 2010, 52 (04) : 1061A - 1061A
12345